COVID-19PulmVasCNCT05374577
Pulmonary Vascular Dysfunction as a Cause of Persistent Exertional Dyspnea After Coronavirus Disease (COVID-19)
An observational study of COVID-19, run by University of Giessen at 1 site in Germany.
Trial summary
To identify pulmonary vascular disease in post/long-COVID-19 patients as a cause of dyspnea/exercise limitation and to differentiate it from other causes of dyspnea Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- COVID-19
- What is being tested?
- pulmonary vascular dysfunction and pulmonary vascular function
- How many people
- 200 participants
- Where
- 1 siteGermany
- Study dates
- 15 Apr 2022to Dec 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with a post-COVID-19 syndrome or a long-COVID-19 syndrome at least 3 months after SARS-CoV-2 infection (symptomatic or asymptomatic); Patients at least 3 months after a SARS-CoV-2 infection (symptomatic or asymptomatic) without post/long-COVID-19.
Who may be able to join
- Age ≥ 18 years, patients with a suspected diagnosis of post/long-COVID-19 syndrome who present to our pneumology or infectious disease outpatient clinic or corresponding ward from the start of the study and whose SARS-CoV-2 infection was diagnosed at least 3 and not longer than 18 months prior to presentation
- Patients at least 3 and not longer than 18 months after a SARS-CoV-2 infection without post/long-COVID-19 syndrome who present to our post-infection outpatient clinic for follow-up
Who cannot join
- Patients who refuse to participate in the study
- Severe underlying chronic pulmonary, cardiac, or systemic disease (e.g., Chronic obstructive pulmonary disease (COPD), severe heart failure, neuromuscular disease) that was diagnosed prior to acute COVID-19 disease and whose progression appears likely as the cause of dyspnea
- Other non pneumologic causes of dyspnea (e.g., hemoglobin < 100 g/L)
- Unstable or acute disease (e.g., acute infection, acute renal failure, acute coronary syndrome)
- Inability to perform spiroergometry, including transient orthopedic problems, contraindications to central venous and arterial catheter placement (e.g., severe bleeding tendency).
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Pulmonary Vascular Dysfunction as a Cause of Persistent Exertional Dyspnea After COVID-19 (PulmVasC)- A Multicenter, Prospective Cohort/Observational Study
To identify pulmonary vascular disease in post/long-COVID-19 patients as a cause of dyspnea/exercise limitation and to differentiate it from other causes of dyspnea
Read the detailed description
The aim is to identify pulmonary vascular disease in post/long-COVID-19 patients as a cause of dyspnea/exercise limitation and to differentiate it from other causes of dyspnea (muscular, left cardiac, psychological, deconditioning-related causes) by investigating ventilation-perfusion (V/Q) mismatch and (exercise-induced) pulmonary hypertension (PH) or right heart dysfunction.
- Conditions
- COVID-19
- Being tested
- pulmonary vascular dysfunction, pulmonary vascular function
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
pulmonary vascular dysfunctionOther
Right ventricular function determined by echocardiography at rest and during exercise (non-invasive estimation of ventilation-perfusion mismatch), systemic endothelial function, left heart function, and plasma levels of vasoactive biomarkers compared with clinical parameters of dyspnea and exercise capacity. Further examinations will be performed in patients with still unclear cause of persistent shortness of breath after 3 months of follow-up (subgroup RHC)
pulmonary vascular functionOther
Right ventricular function determined by echocardiography at rest and during exercise (non-invasive estimation of ventilation-perfusion mismatch), systemic endothelial function, and plasma levels of vasoactive biomarkers compared with clinical parameters of dyspnea and exercise capacity.
| Study group | Role | What they receive |
|---|---|---|
| Patients with a suspected diagnosis of post/long-COVID-19 | Patients with a suspected post-COVID-19 syndrome or a long-COVID-19 syndrome at least 3 months after severe acute respiratory syndrome coronavirus(CoV) type 2 (SARS-CoV-2) infection (symptomatic or asymptomatic) Receives: Other: pulmonary vascular dysfunction | |
| Patients without post/long-COVID-19 Syndrome | Patients at least 3 months after a SARS-CoV-2 infection (symptomatic or asymptomatic) without post/long-COVID-19. Receives: Other: pulmonary vascular function |
What is being measured
The primary outcome is the main question the study is designed to answer.
Measurement of gas exchange under different inhaled oxygen concentrations
Non-invasive estimation of ventilation/perfusion (V/Q) mismatch
Measured: At the time of presentation (on day 1)
Spiroergometric capacity- maximal oxygen uptake (VO2max; ml/min/kg)
Determination of exercise capacity by cardiopulmonary exercise testing (CPET)
Measured: At the time of presentation (on day 1)
Echocardiographic right heart parameters - pulmonary arterial systolic pressure (PASP; mmHg)
Echocardiographic determination of right heart parameters under rest and during exercise
Measured: At the time of presentation (on day 1)
Echocardiographic right heart parameters - Tricuspid annular plane systolic excursion (TAPSE; mm)
Echocardiographic determination of right heart parameters under rest and during exercise
Measured: At the time of presentation (on day 1)
Echocardiographic right heart parameters - right ventricular (RV) end-ventricular volume (EDV; ml)
Echocardiographic determination of right heart parameters under rest and during exercise
Measured: At the time of presentation (on day 1)
Echocardiographic right heart - right volume (RV) end-systolic volume (ESV; ml)
Echocardiographic determination of right heart parameters under rest and during exercise
Measured: At the time of presentation (on day 1)
Echocardiographic right heart - right ventricular longitudinal global strain (%)
Echocardiographic determination of right heart parameters under rest and during exercise
Measured: At the time of presentation (on day 1)
Dyspnoea Index
Determination of dyspnea and functional capacity a questionaire measure of shortness of breath for determining exertion levels
Measured: At the time of presentation (on day 1)
Invasive hemodynamics - pulmonary vascular resistance (PVR; WU)
Invasive measurement of pulmonary hemodynamics by right heart catheterization (RHC subgroup)
Measured: At the time of presentation (on day 1)
Invasive hemodynamics - cardiac Index (CI; l/min/m2)
Invasive measurement of pulmonary hemodynamics by right heart catheterization (RHC subgroup)
Measured: At the time of presentation (on day 1)
Secondary outcomes (11)
Left heart parameters - (E/e' ratio)
Determination of left heart parameters during rest and exercise
Measured: At the time of presentation (on day 1)
Left heart parameters - left ventricular ejection fraction (%)
Determination of left heart parameters during rest and exercise
Measured: At the time of presentation (on day 1)
Pulmonary vascular function
Increase of echocardiographically estimated systolic pulmonary arterial pressure during inhalation of hypoxic gas
Measured: At the time of presentation (on day 1)
Airway Impedance
Determination of airway impedance by oscillometry
Measured: At the time of presentation (on day 1)
Peripheral blood mononuclear cells
Determination of characteristics of peripheral immune cells by fluorescence activated cell sorter (FACS) and functional assays
Measured: At the time of presentation (on day 1)
Shunt measurement
Shunt measurement by contrast-enhanced echocardiography (optional)
Measured: At the time of presentation (on day 1)
Ventilation/Perfusion mismatch
Determination of V/Q mismatch using the gold standard multiple inert gas elimination technique (MIGET) (only in RHC subgroup)
Measured: At the time of presentation (on day 1)
Static and dynamic lung function parameters - vital capacity (VC; L)
Determination of lung function by body plethysmography at rest
Measured: At the time of presentation (on day 1)
Static and dynamic lung function parameters - forced expiratory volume in 1 s (FEV1; L)
Determination of lung function by body plethysmography at rest
Measured: At the time of presentation (on day 1)
Static and dynamic lung function parameters - diffusion capacity (DLCO; %)
Determination of lung function by body plethysmography at rest
Measured: At the time of presentation (on day 1)
Static and dynamic lung function parameters - diffusion coefficient (DLCO/VA; %)
Determination of lung function by body plethysmography at rest
Measured: At the time of presentation (on day 1)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 May 2022
- Study start15 Apr 2022
- Primary completion31 Mar 2025
- Study completionDec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (13)Papers the sponsor has linked to this study.
- Other trials for COVID-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 200 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Giessen
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Natascha Sommer, PD, Principal investigator, Cardiopulmonary Institute (CPI), University of Giessen and Marburg Lung Center (UGMLC)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05374577
- Sponsor's protocol ID
- KKS-300
- Acronym
- PulmVasC
- Status last verified
- Sep 2025
- First submitted
- 29 Apr 2022
- Last updated
- 4 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR, Nordvig AS, Shalev D, Sehrawat TS, Ahluwalia N, Bikdeli B, Dietz D, Der-Nigoghossian C, Liyanage-Don N, Rosner GF, Bernstein EJ, Mohan S, Beckley AA, Seres DS, Choueiri TK, Uriel N, Ausiello JC, Accili D, Freedberg DE, Baldwin M, Schwartz A, Brodie D, Garcia CK, Elkind MSV, Connors JM, Bilezikian JP, Landry DW, Wan EY. Post-acute COVID-19 syndrome. Nat Med. 2021 Apr;27(4):601-615. doi: 10.1038/s41591-021-01283-z. Epub 2021 Mar 22.
PubMed 33753937Gierhardt M, Pak O, Walmrath D, Seeger W, Grimminger F, Ghofrani HA, Weissmann N, Hecker M, Sommer N. Impairment of hypoxic pulmonary vasoconstriction in acute respiratory distress syndrome. Eur Respir Rev. 2021 Sep 15;30(161):210059. doi: 10.1183/16000617.0059-2021. Print 2021 Sep 30.
PubMed 34526314Nuzzi V, Castrichini M, Collini V, Roman-Pognuz E, Di Bella S, Luzzati R, Berlot G, Confalonieri M, Merlo M, Stolfo D, Sinagra G. Impaired Right Ventricular Longitudinal Strain Without Pulmonary Hypertension in Patients Who Have Recovered From COVID-19. Circ Cardiovasc Imaging. 2021 Apr;14(4):e012166. doi: 10.1161/CIRCIMAGING.120.012166. Epub 2021 Apr 8. No abstract available.
PubMed 33827250Rossi R, Coppi F, Monopoli DE, Sgura FA, Arrotti S, Boriani G. Pulmonary arterial hypertension and right ventricular systolic dysfunction in COVID-19 survivors. Cardiol J. 2022;29(1):163-165. doi: 10.5603/CJ.a2021.0159. Epub 2021 Dec 13. No abstract available.
PubMed 34897638Reichenberger F, Voswinckel R, Schulz R, Mensch O, Ghofrani HA, Olschewski H, Seeger W. Noninvasive detection of early pulmonary vascular dysfunction in scleroderma. Respir Med. 2009 Nov;103(11):1713-8. doi: 10.1016/j.rmed.2009.05.004. Epub 2009 Jun 3.
PubMed 19497725Kjaergaard S, Rees S, Malczynski J, Nielsen JA, Thorgaard P, Toft E, Andreassen S. Non-invasive estimation of shunt and ventilation-perfusion mismatch. Intensive Care Med. 2003 May;29(5):727-34. doi: 10.1007/s00134-003-1708-0. Epub 2003 Apr 16.
PubMed 12698242Thomsen LP, Karbing DS, Smith BW, Murley D, Weinreich UM, Kjaergaard S, Toft E, Thorgaard P, Andreassen S, Rees SE. Clinical refinement of the automatic lung parameter estimator (ALPE). J Clin Monit Comput. 2013 Jun;27(3):341-50. doi: 10.1007/s10877-013-9442-9. Epub 2013 Feb 21.
PubMed 23430364Trinkmann F, Benck U, Halder J, Semmelweis A, Saur J, Borggrefe M, Akin I, Kaden JJ. Automated Noninvasive Central Blood Pressure Measurements by Oscillometric Radial Pulse Wave Analysis: Results of the MEASURE-cBP Validation Studies. Am J Hypertens. 2021 Apr 20;34(4):383-393. doi: 10.1093/ajh/hpaa174.
PubMed 33140085Winkler J, Hagert-Winkler A, Wirtz H, Hoheisel G. [Modern impulse oscillometry in the spectrum of pulmonary function testing methods]. Pneumologie. 2009 Aug;63(8):461-9. doi: 10.1055/s-0029-1214938. Epub 2009 Aug 7. German.
PubMed 19670105Wagner PD. The multiple inert gas elimination technique (MIGET). Intensive Care Med. 2008 Jun;34(6):994-1001. doi: 10.1007/s00134-008-1108-6. Epub 2008 Apr 18.
PubMed 18421437Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021 Jan 22;372:n136. doi: 10.1136/bmj.n136. No abstract available.
PubMed 33483331Sonnweber T, Sahanic S, Pizzini A, Luger A, Schwabl C, Sonnweber B, Kurz K, Koppelstatter S, Haschka D, Petzer V, Boehm A, Aichner M, Tymoszuk P, Lener D, Theurl M, Lorsbach-Kohler A, Tancevski A, Schapfl A, Schaber M, Hilbe R, Nairz M, Puchner B, Huttenberger D, Tschurtschenthaler C, Asshoff M, Peer A, Hartig F, Bellmann R, Joannidis M, Gollmann-Tepekoylu C, Holfeld J, Feuchtner G, Egger A, Hoermann G, Schroll A, Fritsche G, Wildner S, Bellmann-Weiler R, Kirchmair R, Helbok R, Prosch H, Rieder D, Trajanoski Z, Kronenberg F, Woll E, Weiss G, Widmann G, Loffler-Ragg J, Tancevski I. Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial. Eur Respir J. 2021 Apr 29;57(4):2003481. doi: 10.1183/13993003.03481-2020. Print 2021 Apr.
PubMed 33303539Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, Horn C, Vanshylla K, Cristanziano VD, Osebold L, Roventa M, Riaz T, Tschernoster N, Altmueller J, Rose L, Salomon S, Priesner V, Luers JC, Albus C, Rosenkranz S, Gathof B, Fatkenheuer G, Hallek M, Klein F, Suarez I, Lehmann C. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health Eur. 2021 Jul;6:100122. doi: 10.1016/j.lanepe.2021.100122. Epub 2021 May 18.
PubMed 34027514
Study at a glance
From the registry record, last updated by the sponsor on 4 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pulmonary Vascular Dysfunction as a Cause of Persistent Exertional Dyspnea After COVID-19 (PulmVasC)- A Multicenter, Prospective Cohort/Observational Study
- ClinicalTrials.gov ID
- NCT05374577
- Acronym / sponsor ID
- PulmVasC / KKS-300
- Conditions
- COVID-19
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 200 participants (actual)
- Lead sponsor
- University of GiessenUniversity, hospital or other
- Study start
- 15 Apr 2022 (actual)
- Primary completion
- 31 Mar 2025 (actual)
- Study completion
- Dec 2025 (estimated)
- First posted
- 16 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To identify pulmonary vascular disease in post/long-COVID-19 patients as a cause of dyspnea/exercise limitation and to differentiate it from other causes of dyspnea
Detailed description
The aim is to identify pulmonary vascular disease in post/long-COVID-19 patients as a cause of dyspnea/exercise limitation and to differentiate it from other causes of dyspnea (muscular, left cardiac, psychological, deconditioning-related causes) by investigating ventilation-perfusion (V/Q) mismatch and (exercise-induced) pulmonary hypertension (PH) or right heart dysfunction.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients with a suspected diagnosis of post/long-COVID-19 | – | Other: pulmonary vascular dysfunctionPatients with a suspected post-COVID-19 syndrome or a long-COVID-19 syndrome at least 3 months after severe acute respiratory syndrome coronavirus(CoV) type 2 (SARS-CoV-2) infection (symptomatic or asymptomatic) |
| Patients without post/long-COVID-19 Syndrome | – | Other: pulmonary vascular functionPatients at least 3 months after a SARS-CoV-2 infection (symptomatic or asymptomatic) without post/long-COVID-19. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with a post-COVID-19 syndrome or a long-COVID-19 syndrome at least 3 months after SARS-CoV-2 infection (symptomatic or asymptomatic); Patients at least 3 months after a SARS-CoV-2 infection (symptomatic or asymptomatic) without post/long-COVID-19.
Key inclusion criteria (2 listed)
- Age ≥ 18 years, patients with a suspected diagnosis of post/long-COVID-19 syndrome who present to our pneumology or infectious disease outpatient clinic or corresponding ward from the start of the study and whose SARS-CoV-2 infection was diagnosed at least 3 and not longer than 18 months prior to presentation
- Patients at least 3 and not longer than 18 months after a SARS-CoV-2 infection without post/long-COVID-19 syndrome who present to our post-infection outpatient clinic for follow-up
Key exclusion criteria (5 listed)
- Patients who refuse to participate in the study
- Severe underlying chronic pulmonary, cardiac, or systemic disease (e.g., Chronic obstructive pulmonary disease (COPD), severe heart failure, neuromuscular disease) that was diagnosed prior to acute COVID-19 disease and whose progression appears likely as the cause of dyspnea
- Other non pneumologic causes of dyspnea (e.g., hemoglobin < 100 g/L)
- Unstable or acute disease (e.g., acute infection, acute renal failure, acute coronary syndrome)
- Inability to perform spiroergometry, including transient orthopedic problems, contraindications to central venous and arterial catheter placement (e.g., severe bleeding tendency).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| pulmonary vascular dysfunctionRight ventricular function determined by echocardiography at rest and during exercise (non-invasive estimation of ventilation-perfusion mismatch), systemic endothelial function, left heart function, and plasma levels of vasoactive biomarkers compared with clinical parameters of dyspnea and exercise capacity. Further examinations will be performed in patients with still unclear cause of persistent shortness of breath after 3 months of follow-up (subgroup RHC) | Other | Patients with a suspected diagnosis of post/long-COVID-19 |
| pulmonary vascular functionRight ventricular function determined by echocardiography at rest and during exercise (non-invasive estimation of ventilation-perfusion mismatch), systemic endothelial function, and plasma levels of vasoactive biomarkers compared with clinical parameters of dyspnea and exercise capacity. | Other | Patients without post/long-COVID-19 Syndrome |
Primary outcome
Measurement of gas exchange under different inhaled oxygen concentrations
Time frame: At the time of presentation (on day 1)
Non-invasive estimation of ventilation/perfusion (V/Q) mismatch
Spiroergometric capacity- maximal oxygen uptake (VO2max; ml/min/kg)
Time frame: At the time of presentation (on day 1)
Determination of exercise capacity by cardiopulmonary exercise testing (CPET)
Echocardiographic right heart parameters - pulmonary arterial systolic pressure (PASP; mmHg)
Time frame: At the time of presentation (on day 1)
Echocardiographic determination of right heart parameters under rest and during exercise
Echocardiographic right heart parameters - Tricuspid annular plane systolic excursion (TAPSE; mm)
Time frame: At the time of presentation (on day 1)
Echocardiographic determination of right heart parameters under rest and during exercise
Echocardiographic right heart parameters - right ventricular (RV) end-ventricular volume (EDV; ml)
Time frame: At the time of presentation (on day 1)
Echocardiographic determination of right heart parameters under rest and during exercise
Echocardiographic right heart - right volume (RV) end-systolic volume (ESV; ml)
Time frame: At the time of presentation (on day 1)
Echocardiographic determination of right heart parameters under rest and during exercise
Echocardiographic right heart - right ventricular longitudinal global strain (%)
Time frame: At the time of presentation (on day 1)
Echocardiographic determination of right heart parameters under rest and during exercise
Dyspnoea Index
Time frame: At the time of presentation (on day 1)
Determination of dyspnea and functional capacity a questionaire measure of shortness of breath for determining exertion levels
Invasive hemodynamics - pulmonary vascular resistance (PVR; WU)
Time frame: At the time of presentation (on day 1)
Invasive measurement of pulmonary hemodynamics by right heart catheterization (RHC subgroup)
Invasive hemodynamics - cardiac Index (CI; l/min/m2)
Time frame: At the time of presentation (on day 1)
Invasive measurement of pulmonary hemodynamics by right heart catheterization (RHC subgroup)
11 secondary outcomes
Left heart parameters - (E/e' ratio)
Time frame: At the time of presentation (on day 1)
Left heart parameters - left ventricular ejection fraction (%)
Time frame: At the time of presentation (on day 1)
Pulmonary vascular function
Time frame: At the time of presentation (on day 1)
Airway Impedance
Time frame: At the time of presentation (on day 1)
Peripheral blood mononuclear cells
Time frame: At the time of presentation (on day 1)
Shunt measurement
Time frame: At the time of presentation (on day 1)
Ventilation/Perfusion mismatch
Time frame: At the time of presentation (on day 1)
Static and dynamic lung function parameters - vital capacity (VC; L)
Time frame: At the time of presentation (on day 1)
Static and dynamic lung function parameters - forced expiratory volume in 1 s (FEV1; L)
Time frame: At the time of presentation (on day 1)
Static and dynamic lung function parameters - diffusion capacity (DLCO; %)
Time frame: At the time of presentation (on day 1)
Static and dynamic lung function parameters - diffusion coefficient (DLCO/VA; %)
Time frame: At the time of presentation (on day 1)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Sep 2025.
- Background: PubMed 33753937Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR, Nordvig AS, Shalev D, Sehrawat TS, Ahluwalia N, Bikdeli B, Dietz D, Der-Nigoghossian C, Liyanage-Don N, Rosner GF, Bernstein EJ, Mohan S, Beckley AA, Seres DS, Choueiri TK, Uriel N, Ausiello JC, Accili D, Freedberg DE, Baldwin M, Schwartz A, Brodie D, Garcia CK, Elkind MSV, Connors JM, Bilezikian JP, Landry DW, Wan EY. Post-acute COVID-19 syndrome. Nat Med. 2021 Apr;27(4):601-615. doi: 10.1038/s41591-021-01283-z. Epub 2021 Mar 22.
- Background: PubMed 34526314Gierhardt M, Pak O, Walmrath D, Seeger W, Grimminger F, Ghofrani HA, Weissmann N, Hecker M, Sommer N. Impairment of hypoxic pulmonary vasoconstriction in acute respiratory distress syndrome. Eur Respir Rev. 2021 Sep 15;30(161):210059. doi: 10.1183/16000617.0059-2021. Print 2021 Sep 30.
- Background: PubMed 33827250Nuzzi V, Castrichini M, Collini V, Roman-Pognuz E, Di Bella S, Luzzati R, Berlot G, Confalonieri M, Merlo M, Stolfo D, Sinagra G. Impaired Right Ventricular Longitudinal Strain Without Pulmonary Hypertension in Patients Who Have Recovered From COVID-19. Circ Cardiovasc Imaging. 2021 Apr;14(4):e012166. doi: 10.1161/CIRCIMAGING.120.012166. Epub 2021 Apr 8. No abstract available.
- Background: PubMed 34897638Rossi R, Coppi F, Monopoli DE, Sgura FA, Arrotti S, Boriani G. Pulmonary arterial hypertension and right ventricular systolic dysfunction in COVID-19 survivors. Cardiol J. 2022;29(1):163-165. doi: 10.5603/CJ.a2021.0159. Epub 2021 Dec 13. No abstract available.
- Background: PubMed 19497725Reichenberger F, Voswinckel R, Schulz R, Mensch O, Ghofrani HA, Olschewski H, Seeger W. Noninvasive detection of early pulmonary vascular dysfunction in scleroderma. Respir Med. 2009 Nov;103(11):1713-8. doi: 10.1016/j.rmed.2009.05.004. Epub 2009 Jun 3.
- Background: PubMed 12698242Kjaergaard S, Rees S, Malczynski J, Nielsen JA, Thorgaard P, Toft E, Andreassen S. Non-invasive estimation of shunt and ventilation-perfusion mismatch. Intensive Care Med. 2003 May;29(5):727-34. doi: 10.1007/s00134-003-1708-0. Epub 2003 Apr 16.
- Background: PubMed 23430364Thomsen LP, Karbing DS, Smith BW, Murley D, Weinreich UM, Kjaergaard S, Toft E, Thorgaard P, Andreassen S, Rees SE. Clinical refinement of the automatic lung parameter estimator (ALPE). J Clin Monit Comput. 2013 Jun;27(3):341-50. doi: 10.1007/s10877-013-9442-9. Epub 2013 Feb 21.
- Background: PubMed 33140085Trinkmann F, Benck U, Halder J, Semmelweis A, Saur J, Borggrefe M, Akin I, Kaden JJ. Automated Noninvasive Central Blood Pressure Measurements by Oscillometric Radial Pulse Wave Analysis: Results of the MEASURE-cBP Validation Studies. Am J Hypertens. 2021 Apr 20;34(4):383-393. doi: 10.1093/ajh/hpaa174.
- Background: PubMed 19670105Winkler J, Hagert-Winkler A, Wirtz H, Hoheisel G. [Modern impulse oscillometry in the spectrum of pulmonary function testing methods]. Pneumologie. 2009 Aug;63(8):461-9. doi: 10.1055/s-0029-1214938. Epub 2009 Aug 7. German.
- Background: PubMed 18421437Wagner PD. The multiple inert gas elimination technique (MIGET). Intensive Care Med. 2008 Jun;34(6):994-1001. doi: 10.1007/s00134-008-1108-6. Epub 2008 Apr 18.
- Background: PubMed 33483331Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021 Jan 22;372:n136. doi: 10.1136/bmj.n136. No abstract available.
- Background: PubMed 33303539Sonnweber T, Sahanic S, Pizzini A, Luger A, Schwabl C, Sonnweber B, Kurz K, Koppelstatter S, Haschka D, Petzer V, Boehm A, Aichner M, Tymoszuk P, Lener D, Theurl M, Lorsbach-Kohler A, Tancevski A, Schapfl A, Schaber M, Hilbe R, Nairz M, Puchner B, Huttenberger D, Tschurtschenthaler C, Asshoff M, Peer A, Hartig F, Bellmann R, Joannidis M, Gollmann-Tepekoylu C, Holfeld J, Feuchtner G, Egger A, Hoermann G, Schroll A, Fritsche G, Wildner S, Bellmann-Weiler R, Kirchmair R, Helbok R, Prosch H, Rieder D, Trajanoski Z, Kronenberg F, Woll E, Weiss G, Widmann G, Loffler-Ragg J, Tancevski I. Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial. Eur Respir J. 2021 Apr 29;57(4):2003481. doi: 10.1183/13993003.03481-2020. Print 2021 Apr.
Related trials for COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Natascha Sommer, PD principal investigator
Cardiopulmonary Institute (CPI), University of Giessen and Marburg Lung Center (UGMLC)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID-19, run by University of Giessen at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 4 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Measurement of gas exchange under different inhaled oxygen concentrations (time frame: At the time of presentation (on day 1)). The study lists 10 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05374577, which also lists 13 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2025.